IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.17

21 Oct
2021

-0.010

OPEN

$0.18

-5.56%

HIGH

$0.18

9,336,715

LOW

$0.15

TARGET
$0.21 23.5% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 1.7 - 1.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-1.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx8.4 M
Book Value Per Share xxxxxxxxxxxxxxx1.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-13.3 M
Net Profit Margin xxxxxxxxxxxxxxx-246.24 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx-78.32 %
Return on Invested Capital xxxxxxxxxxxxxxx-77.35 %
Return on Assets xxxxxxxxxxxxxxx-61.56 %
Return on Equity xxxxxxxxxxxxxxx-78.32 %
Return on Total Capital xxxxxxxxxxxxxxx-84.90 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-13.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

20/10/2021

1

Add

$0.21

23.53%

The PREVENT trial has met its primary endpoint and was statistically significant. This, says the broker, is a major milestone in the Impedimed history. The next step is peer review and publication in medical journals.

Unfortunately, due to covid delays this is still a couple of months away. In the meantime, Speculative Buy and 21c target retained.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -1.10 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -0.60 cents.

IPD STOCK CHART